The protective role of dapagliflozin on the noreflow phenomenon in type 2 diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention

dc.authorid0000-0002-5711-8873
dc.contributor.authorKoseoglu, Cemal
dc.contributor.authorConer, Ali
dc.contributor.authorOncel, Can Ramazan
dc.date.accessioned2026-01-24T12:31:24Z
dc.date.available2026-01-24T12:31:24Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.doi10.1080/00015385.2025.2511523
dc.identifier.endpage534
dc.identifier.issn0001-5385
dc.identifier.issn1784-973X
dc.identifier.issue5
dc.identifier.pmid40420809
dc.identifier.scopus2-s2.0-105007012268
dc.identifier.scopusqualityQ3
dc.identifier.startpage534
dc.identifier.urihttps://doi.org/10.1080/00015385.2025.2511523
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5843
dc.identifier.volume80
dc.identifier.wosWOS:001497848600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofActa Cardiologica
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.titleThe protective role of dapagliflozin on the noreflow phenomenon in type 2 diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention
dc.typeLetter

Dosyalar